• This record comes from PubMed

2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension

. 2013 Oct ; 31 (10) : 1925-38.

Language English Country Netherlands Media print

Document type Journal Article, Practice Guideline

Persistent link   https://www.medvik.cz/link/pmid24107724
Links

PubMed 24107724
DOI 10.1097/hjh.0b013e328364ca4c
PII: 00004872-201310000-00002
Knihovny.cz E-resources

References provided by Crossref.org

Newest 20 citations...

See more in
Medvik | PubMed

Risk factors for carotid plaque progression after optimising the risk factor treatment: substudy results of the Atherosclerotic Plaque Characteristics Associated with a Progression Rate of the Plaque and a Risk of Stroke in Patients with the carotid Bifurcation Plaque Study (ANTIQUE)

. 2022 Apr ; 7 (2) : 132-139. [epub] 20211201

20-Hydroxyeicosatetraenoic acid antagonist attenuates the development of malignant hypertension and reverses it once established: a study in Cyp1a1-Ren-2 transgenic rats

. 2018 Oct 31 ; 38 (5) : . [epub] 20180912

Two pharmacological epoxyeicosatrienoic acid-enhancing therapies are effectively antihypertensive and reduce the severity of ischemic arrhythmias in rats with angiotensin II-dependent hypertension

. 2018 Jun ; 36 (6) : 1326-1341.

Variation in GP decisions on antihypertensive treatment in oldest-old and frail individuals across 29 countries

. 2017 Apr 20 ; 17 (1) : 93. [epub] 20170420

Epoxyeicosatrienoic acid analog attenuates the development of malignant hypertension, but does not reverse it once established: a study in Cyp1a1-Ren-2 transgenic rats

. 2016 Oct ; 34 (10) : 2008-25.

LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial

. 2016 Jun ; 34 (6) : 1140-50.

Find record

Citation metrics

Archiving options